Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

Cited In for PubMed (Select 23139211)

1.

A pathway-centric survey of somatic mutations in Chinese patients with colorectal carcinomas.

Ling C, Wang L, Wang Z, Xu L, Sun L, Yang H, Li WD, Wang K.

PLoS One. 2015 Jan 24;10(1):e0116753. doi: 10.1371/journal.pone.0116753. eCollection 2015.

2.

Analysis of tumor suppressor genes based on gene ontology and the KEGG pathway.

Yang J, Chen L, Kong X, Huang T, Cai YD.

PLoS One. 2014 Sep 10;9(9):e107202. doi: 10.1371/journal.pone.0107202. eCollection 2014.

3.

Tumor suppressor microRNA-27a in colorectal carcinogenesis and progression by targeting SGPP1 and Smad2.

Bao Y, Chen Z, Guo Y, Feng Y, Li Z, Han W, Wang J, Zhao W, Jiao Y, Li K, Wang Q, Wang J, Zhang H, Wang L, Yang W.

PLoS One. 2014 Aug 28;9(8):e105991. doi: 10.1371/journal.pone.0105991. eCollection 2014.

4.

Functional and genetic analysis of the colon cancer network.

Emmert-Streib F, de Matos Simoes R, Glazko G, McDade S, Haibe-Kains B, Holzinger A, Dehmer M, Campbell F.

BMC Bioinformatics. 2014;15 Suppl 6:S6. doi: 10.1186/1471-2105-15-S6-S6. Epub 2014 May 16.

5.

From genotype to functional phenotype: unraveling the metabolomic features of colorectal cancer.

Bathe OF, Farshidfar F.

Genes (Basel). 2014 Jul 22;5(3):536-60. doi: 10.3390/genes5030536.

6.

Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer.

Shanmugam V, Ramanathan RK, Lavender NA, Sinari S, Chadha M, Liang WS, Kurdoglu A, Izatt T, Christoforides A, Benson H, Phillips L, Baker A, Murray C, Hostetter G, Von Hoff DD, Craig DW, Carpten JD.

BMC Med Genomics. 2014 Jun 18;7:36. doi: 10.1186/1755-8794-7-36.

7.

Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis.

Choi SH, Kim BG, Robinson J, Fink S, Yan M, Sporn MB, Markowitz SD, Letterio JJ.

J Clin Invest. 2014 Jun;124(6):2472-82. doi: 10.1172/JCI69672. Epub 2014 May 16.

8.

Epigenetic inactivation of the candidate tumor suppressor USP44 is a frequent and early event in colorectal neoplasia.

Sloane MA, Wong JW, Perera D, Nunez AC, Pimanda JE, Hawkins NJ, Sieber OM, Bourke MJ, Hesson LB, Ward RL.

Epigenetics. 2014 Aug;9(8):1092-100. doi: 10.4161/epi.29222. Epub 2014 May 16.

9.

Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells.

Diesch J, Sanij E, Gilan O, Love C, Tran H, Fleming NI, Ellul J, Amalia M, Haviv I, Pearson RB, Tulchinsky E, Mariadason JM, Sieber OM, Hannan RD, Dhillon AS.

PLoS One. 2014 Mar 21;9(3):e88950. doi: 10.1371/journal.pone.0088950. eCollection 2014.

10.

Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer.

Coppedè F, Lopomo A, Spisni R, Migliore L.

World J Gastroenterol. 2014 Jan 28;20(4):943-56. doi: 10.3748/wjg.v20.i4.943. Review.

11.

An integrative CGH, MSI and candidate genes methylation analysis of colorectal tumors.

Brim H, Abu-Asab MS, Nouraie M, Salazar J, Deleo J, Razjouyan H, Mokarram P, Schaffer AA, Naghibhossaini F, Ashktorab H.

PLoS One. 2014 Jan 27;9(1):e82185. doi: 10.1371/journal.pone.0082185. eCollection 2014.

12.

Attenuation of TGF-β signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model.

Biswas T, Gu X, Yang J, Ellies LG, Sun LZ.

Cancer Lett. 2014 Apr 28;346(1):129-38. doi: 10.1016/j.canlet.2013.12.018. Epub 2013 Dec 22.

13.

Novel genes associated with colorectal cancer are revealed by high resolution cytogenetic analysis in a patient specific manner.

Eldai H, Periyasamy S, Al Qarni S, Al Rodayyan M, Muhammed Mustafa S, Deeb A, Al Sheikh E, Afzal M, Johani M, Yousef Z, Aziz MA.

PLoS One. 2013 Oct 30;8(10):e76251. doi: 10.1371/journal.pone.0076251. eCollection 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/3f97e271-6926-4766-8430-1b4a009e80c6. Afzal Khan, Mohammed [corrected to Afzal, Mohammed].

14.

Transforming growth factor β regulates P-body formation through induction of the mRNA decay factor tristetraprolin.

Blanco FF, Sanduja S, Deane NG, Blackshear PJ, Dixon DA.

Mol Cell Biol. 2014 Jan;34(2):180-95. doi: 10.1128/MCB.01020-13. Epub 2013 Nov 4.

15.

TGF-β: an emerging player in drug resistance.

Brunen D, Willems SM, Kellner U, Midgley R, Simon I, Bernards R.

Cell Cycle. 2013 Sep 15;12(18):2960-8. doi: 10.4161/cc.26034. Epub 2013 Aug 12.

16.

Genomic instability and colon carcinogenesis: from the perspective of genes.

Rao CV, Yamada HY.

Front Oncol. 2013 May 21;3:130. doi: 10.3389/fonc.2013.00130. eCollection 2013.

17.

CD133: a cancer stem cells marker, is used in colorectal cancers.

Ren F, Sheng WQ, Du X.

World J Gastroenterol. 2013 May 7;19(17):2603-11. doi: 10.3748/wjg.v19.i17.2603. Review.

18.

TGF-Beta suppresses VEGFA-mediated angiogenesis in colon cancer metastasis.

Geng L, Chaudhuri A, Talmon G, Wisecarver JL, Wang J.

PLoS One. 2013;8(3):e59918. doi: 10.1371/journal.pone.0059918. Epub 2013 Mar 25.

19.

Aptamers and their potential to selectively target aspects of EGF, Wnt/β-catenin and TGFβ-smad family signaling.

Conidi A, van den Berghe V, Huylebroeck D.

Int J Mol Sci. 2013 Mar 26;14(4):6690-719. doi: 10.3390/ijms14046690. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk